Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

Completed · Phase 3 · Has a placebo group

Conditions studied: Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful

In brief

The purpose of this study is to explore the overall safety profile and durability of efficacy of Engensis (VM202) in painful diabetic peripheral neuropathy. All subjects still in follow-up for the VMDN-003 study or who have completed the Day 270 visit within the prior 90 days will be approached to enroll in the long-term safety extension study.

Key facts

Study ID
NCT04055090
Run by
Helixmith Co., Ltd.
People needed
101
Starts
2019-02-04
Expected to finish
2019-07-24
Last updated by the study team
2025-10-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.